Analysis of phase III IMpower132 trial evaluating the addition of atezolizumab to first-line chemotherapy in NSCLC: PFS, safety, and interim OS.
Results from phase I/III IMpower133 trial evaluating addition of atezolizumab to first-line chemotherapy in extensive-stage SCLC from WCLC 2018 reported by Clinical Care Options (CCO).
Results from PACIFIC trial of durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC from WCLC 2018 reported by Clinical Care Options (CCO).
Interim analysis of the phase III ALTA-1L trial of brigatinib vs crizotinib in ALK inhibitor–naive patients with ALK-positive advanced NSCLC
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.